摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline | 874278-30-5

中文名称
——
中文别名
——
英文名称
5-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline
英文别名
5-((4-(2-(4-tert-butylphenyl)-1H-benzo[d]imidazol-4-yl)piperazin-1-yl)methyl)quinoxaline;5-[[4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl]methyl]quinoxaline
5-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline化学式
CAS
874278-30-5
化学式
C30H32N6
mdl
——
分子量
476.624
InChiKey
MRIRODCBQYGJJC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    36
  • 可旋转键数:
    5
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    60.9
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    草酸醛2-amino-3-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)phenylamine甲醇 为溶剂, 反应 18.0h, 以38%的产率得到5-({4-[2-(4-tert-butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline
    参考文献:
    名称:
    Discovery of 6-({4-[2-(4-tert-Butylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): An Orally Active Antagonist of the Gonadotropin Releasing Hormone Receptor (GnRH-R)
    摘要:
    A potent, highly insoluble, GnRH antagonist with a 2-phenyl-4-piperazinylbenzimidazole template and a quinoxaline-2,3-dione pharmacophore was modified to maintain GnRH antagonist activity and improve in vitro pharmaceutical properties. Structural changes to the quinoxaline-2,3-dione portion of the molecule resulted in several structures with improved properties and culminated in the discovery of 6-((4-[2-(4-tertbutylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024). The compound was shown to have excellent pharmacokinetic parameters and lowered rat plasma LH levels after oral administration.
    DOI:
    10.1021/jm801572m
点击查看最新优质反应信息

文献信息

  • Gonadotropin releasing hormone receptor antagonists
    申请人:Garrick Michael Lloyd
    公开号:US20060019965A1
    公开(公告)日:2006-01-26
    The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.
    本发明涉及促性腺激素释放激素(“GnRH”)(也称为促黄体生成激素释放激素)受体拮抗剂。
  • GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS
    申请人:Wyeth
    公开号:EP1758895A1
    公开(公告)日:2007-03-07
  • US7696210B2
    申请人:——
    公开号:US7696210B2
    公开(公告)日:2010-04-13
  • [EN] GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DE RÉCEPTEURS DE L'HORMONE DE LIBÉRATION DE GONADOTROPHINES
    申请人:WYETH CORP
    公开号:WO2006009734A1
    公开(公告)日:2006-01-26
    The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.
  • Discovery of 6-({4-[2-(4-<i>tert</i>-Butylphenyl)-1<i>H</i>-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024): An Orally Active Antagonist of the Gonadotropin Releasing Hormone Receptor (GnRH-R)
    作者:Jeffrey C. Pelletier、Murty V. Chengalvala、Joshua E. Cottom、Irene B. Feingold、Daniel M. Green、Diane B. Hauze、Christine A. Huselton、James W. Jetter、Gregory S. Kopf、Joseph T. Lundquist、Ronald L. Magolda、Charles W. Mann、John F. Mehlmann、John F. Rogers、Linda K. Shanno、William R. Adams、Cesario O. Tio、Jay E. Wrobel
    DOI:10.1021/jm801572m
    日期:2009.4.9
    A potent, highly insoluble, GnRH antagonist with a 2-phenyl-4-piperazinylbenzimidazole template and a quinoxaline-2,3-dione pharmacophore was modified to maintain GnRH antagonist activity and improve in vitro pharmaceutical properties. Structural changes to the quinoxaline-2,3-dione portion of the molecule resulted in several structures with improved properties and culminated in the discovery of 6-((4-[2-(4-tertbutylphenyl)-1H-benzimidazol-4-yl]piperazin-1-yl}methyl)quinoxaline (WAY-207024). The compound was shown to have excellent pharmacokinetic parameters and lowered rat plasma LH levels after oral administration.
查看更多